May 26, 2022
CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA – May 26, 2022 – Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
May 25, 2022
George Painter, Emory Professor and CEO of DRIVE, awarded $52 million to co-lead Antiviral Countermeasures Development Center ATLANTA, May 25, 2022 – Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
Feb 11, 2022
Altesa Bioscience Inc. has raised seed financing to develop drugs for viral diseases.
Feb 10, 2022
https://www.altesabio.com/wp-content/uploads/2022/02/NR_ALTESA_LAUNCHES_OPS_02.10.2022.pdf
Feb 10, 2022
Hard DRIVE for virus fixes: Altesa, Emory take on global threats.
Recent Comments